Delivery Order SPE2DR25D2206-SPE2DR26F9JA2
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $42,932.71 by the Defense Logistics Agency (DLA) on August 19, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors. This firm fixed price, non-set-aside contract is scheduled for completion by August 20, 2025, and will be fulfilled at the company's Conshohocken facility. The award represents a child order under AmerisourceBergen's...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, received a delivery order award from the Defense Logistics Agency valued at $15,727.17 for REPATHA 140 mg/mL SureClick auto-injectors. The contract was awarded on December 11, 2025, with an ultimate completion date of December 12, 2025, under a firm fixed-price arrangement with no set-aside designation. This delivery order is issued against AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $4,598.24 by the Defense Logistics Agency (DLA) on December 21, 2025, for REPATHA 140 mg/ml SureClick auto-injectors. This firm fixed-price delivery order, with an ultimate completion date of December 22, 2025, represents a non-competitive set-aside procurement and will be performed at the company's corporate office location in Conshohocken, PA....
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $13,542.27 for Repatha 140 mg/ml SureClick auto-injectors by the Defense Logistics Agency on November 18, 2025, with an ultimate completion date of November 19, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $21,054.69 on October 31, 2025, for the supply of Repatha 140 mg/mL SureClick auto-injectors. This firm fixed-price delivery order, which is expected to be completed by November 3, 2025, was competitively awarded without a set-aside designation by the Defense Logistics Agency (DLA), a component of the Department of Defense responsible for managing...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor based in Conshohocken, Pennsylvania, received a $26,343.44 delivery order from the Defense Logistics Agency on November 3, 2025, for REPATHA 140 mg/mL SureClick auto-injectors. This firm fixed price delivery order, which has no set-aside designation, is scheduled for completion by November 4, 2025, and will be fulfilled at the contractor's Conshohocken facility. The award represents a single delivery order under...
- The Defense Logistics Agency awarded a delivery order valued at $1,955.33 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors. This competitive award, issued on December 11, 2025, with an ultimate completion date of December 12, 2025, represents a firm fixed-price transaction with no set-aside designation. The drug will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $35,697.41 by the Defense Logistics Agency for REPATHA 140 mg/ml SureClick auto-injector medication. The award was made on August 21, 2025, with an ultimate completion date of August 22, 2025, under a firm fixed-price delivery order structure with no set-aside designation. This competitive award is issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $35,772.20 on September 19, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors. This firm fixed-price delivery order, with an ultimate completion date of September 22, 2025, was issued without a set-aside designation and represents a competitively awarded procurement through the Defense Logistics Agency's Medical Supply Chain. The...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $5,857.21 by the Defense Logistics Agency (DLA) on December 11, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injectors. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of December 12, 2025, and represents performance at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9JA2Delivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $29,007.77 by the Defense Logistics Agency on December 31, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors. This is a firm fixed-price, non-competitive delivery order with an ultimate completion date of January 2, 2026. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026, which serves as the primary vehicle for the company to supply pharmaceutical products and medical supplies to support military healthcare systems worldwide. The DLA, responsible for providing logistics and supply chain support to the Department of Defense, utilizes these delivery orders to procure critical medical commodities for military personnel and veterans. REPATHA (evolocumab) is a specialty biopharmaceutical used to treat high cholesterol, reflecting the breadth of therapeutic areas supported through AmerisourceBergen's federal pharmaceutical distribution network. As the prime contractor on this award, AmerisourceBergen leverages its established capabilities to fulfill federal procurement requirements efficiently, supporting healthcare delivery across the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $29.0k | 12/30/25 |